R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

How to craft responsive clinical trials that are designed fo...

Without the right design, right data and right decisions, idealised clinical trial plans cannot be translated into blueprints for robust studies.

Views & Analysis

Searching for new hope in Alzheimer’s

For the best part of two decades, it seemed as if pharma hit a brick wall as it tried to find new treatments for Alzheimer’s.

Views & Analysis

Q-and-A-Albireo’s-Ron-Cooper-on-bile-acid-modulation

Q&A: Albireo’s Ron Cooper on bile acid modulation

While bile acids might not be as trendy as gene editing, modulating them has potential for first-in-class therapies for liver diseases.

Views & Analysis

QandA-Sangamos-Duncan-McKay-on-genomic-medicines

Q&A: Sangamo’s Duncan McKay on genomic medicines

We talk to Duncan McKay, senior vice president and general manager, Europe of Sangamo Therapeutics, about the future of genomic medicines and how healthcare systems may need to adapt to

Views & Analysis

Q&A: Adaptimmune’s Elliot Norry on cell therapy

Dr Elliot N

Views & Analysis

Bridging the gap between industry and charities: Enabling PP...

Public and patient involvement (PPI) in clinical research is the new normal, but bridging the gap between how industry and charities work isn’t always easy.

How to craft responsive clinical trials that are designed fo...

Searching for new hope in Alzheimer’s

Q&A: Albireo’s Ron Cooper on bile acid modulation

Q&A: Sangamo’s Duncan McKay on genomic medicines

Q&A: Adaptimmune’s Elliot Norry on cell therapy

Bridging the gap between industry and charities: Enabling PP...

Sanofi gives up on amlitelimab in atopic dermatitis

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks